A carregar...
A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose‐expansion cohort
The maximum tolerated dose of the panobinostat and carfilzomib combination in patients with relapsed/refractory multiple myeloma (RRMM) was not reached in our previous dose‐escalation study. We report additional dose levels in the phase I/II, single‐arm, multicenter, standard 3 + 3 dose‐escalation e...
Na minha lista:
| Publicado no: | Am J Hematol |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons, Inc.
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7986798/ https://ncbi.nlm.nih.gov/pubmed/33421178 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.26088 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|